<DOC>
	<DOCNO>NCT01988324</DOCNO>
	<brief_summary>Knowledge breast cancer estrogen receptor ( ER ) expression major importance treatment-decision making . Patients ER-positive tumor treat anti-oestrogen therapy , relatively side effect compare chemotherapy . Whole-body tumor ER-expression visualize 18F-fluoroestradiol PET imaging ( FES-PET ) . In addition ER , androgen receptor ( AR ) potential new target breast cancer . PET image 18F-fluorodihydrotestosterone ( 18F-FDHT ) may allow visualization tumor AR-expression . In current study perform FES-PET FDHT-PET metastatic breast cancer patient evaluate concordance concurrent biopsy . Molecular image tumor AR- ER-expression may well value future treatment decision-making .</brief_summary>
	<brief_title>AR ER Imaging Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Metastatic breast cancer , least one know metastasis outside liver 2 . Presence lesion safely accessible tumor biopsy ( may liver lesion ) 3 . Postmenopausal status define one following : age ≥60 year previous bilateral oophorectomy age &lt; 60 year amenorrhea &gt; 12 month absence interfere hormonal therapy ( LHRH agonists ERantagonists ) patient age &lt; 60 year use ERantagonist amenorrhea &gt; 12 month FSH &gt; 24 U/L LH &gt; 14 U/L e. patient age &lt; 60 year use LHRH agonist continue LHRHagonists PET procedure 4 . Initially ERpositive tumor histology . 5 . ECOG performance status 02 . 6 . Signed write informed consent 7 . Able comply protocol 1 . Use estrogen receptor ligand , include tamoxifen , fulvestrant estrogen , androgen receptor ligands , 6 week entry study 2 . Lifeexpectancy ≤ 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>